Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Pramiracetam | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 400-1200 mg/day divided into 2-3 doses | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | With fat-containing meals (fat-soluble). Morning and early afternoon dosing preferred. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Cycles of 8-12 weeks on, 4 weeks off | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | moderate_human | moderate_human |
Potently stimulates high-affinity choline uptake (HACU) in hippocampal synaptosomes, the rate-limiting step in acetylcholine synthesis. This profoundly enhances cholinergic neurotransmission without direct receptor agonism. Approximately 10-30x more potent than piracetam on a per-milligram basis. Does not significantly affect other neurotransmitter systems, making it a highly targeted cholinergic enhancer.
400-1200 mg/day divided into 2-3 doses
With fat-containing meals (fat-soluble). Morning and early afternoon dosing preferred.
Cycles of 8-12 weeks on, 4 weeks off
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →